'Code Blue' equals lower survival for cancer patients

August 01, 2017

Patients with advanced cancer who suffer cardiac arrest in the hospital have a survival rate of less than 10 percent--half the rate of other patients without cancer, according to a nationwide study led by the University of Rochester Medical Center.

The data helps to clear up some myths in medicine about cardiac arrest survival and can be used as a guidepost when hospitalized cancer patients and their families consider do-not-resuscitate (DNR) orders, said Jeffrey T. Buckel, M.D., a third-year postdoctoral fellow in cardiology at URMC, who led the research.

"We're hopeful that our study in some way will help doctors and cancer patients make more informed decisions about the end of life," Buckel said. "It's very important to have early, frank, discussions around the goals of care."

The study was published by the Journal of Oncology Practice in a special end-of-life care edition.

Researchers from Rochester and collaborating institutions used a nationwide resuscitation registry to evaluate survival after cardiac arrest of more than 47,000 people at 369 hospitals. Patients who were in for surgery (before, during, and after), emergency room treatment, rehabilitation, or treatment from cardiac catheterization labs or interventional radiology were excluded from the study, as were patients with implantable defibrillators. Of the 47,157 patients who experienced cardiac arrest, 6,585 or 14 percent had advanced cancer at the time of the arrest.

Researchers also looked at how resuscitation efforts occurred. Another myth in medicine is that patients with advanced cancer receive less aggressive resuscitation care, but researchers found no evidence of that happening, Buckel said.

In fact, the average time that doctors worked to resuscitate all patients (cancer and non-cancer) ranged from about 22 to 24 minutes, the study showed.

However, after cancer patients were successfully resuscitated, they more often signed DNR orders during the next 48 hours.

When outcomes of cancer and non-cancer patients were compared, results showed that 57.5 percent of the cancer patients were resuscitated successfully but only 9.6 percent survived to be discharged from the hospital; whereas 63 percent of the non-cancer patients were successfully resuscitated and 19.2 percent survived to the time of discharge.

Researchers reported several limitations to the study, including a lack of detailed data on the types of advanced cancer and cancer treatments being given used at the time of cardiac arrest.
-end-
The National Heart Lung and Blood Institute and the Veterans Administration funded the study. Senior author is Brahmajee K. Nallamothu, M.D., professor of Cardiology at the University of Michigan and Buckel's mentor while he trained in Michigan prior to coming to Rochester. Other collaborators were from the Dartmouth-Hitchcock Medical Center, St. Luke's Mid-America Heart Institute, University of Missouri-Kansas City, and Minneapolis Heart Institute.

The University of Rochester Medical Center is home to approximately 3,000 individuals who conduct research on everything from cancer and heart disease to Parkinson's, pandemic influenza, and autism. Spread across many centers, institutes, and labs, our scientists have developed therapies that have improved human health locally, in the region, and across the globe. To learn more, visit urmc.rochester.edu/research.

University of Rochester Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.